Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
about
Recent advances in treating Parkinson's disease.Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.Novel Levodopa Formulations for Parkinson's Disease.Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations
P2860
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@en
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@nl
type
label
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@en
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@nl
prefLabel
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@en
Conversion to IPX066 from Stan ...... Experience in Clinical Trials.
@nl
P2093
P2860
P356
P1476
Conversion to IPX066 from Stan ...... Experience in Clinical Trials
@en
P2093
Carlos Singer
Joerg Spiegel
Lawrence Elmer
Paul A Nausieda
Ramon A Gil
Robert Rubens
Sarita Khanna
Sherron Kell
Suneel Gupta
P2860
P304
P356
10.3233/JPD-150622
P577
2015-01-01T00:00:00Z